Lunai Bioworks signs exclusive Parkinson’s cellular phenotyping deal with Tanaist
LNAI•Builds on Augusta AI analysis
The work builds on Augusta AI analysis of 650 PPMI participants with 4,500 proteomic probes that identified three Parkinson’s subtypes.
Ownership of collaboration results
Lunai will own collaboration-generated analyses, biomarker findings, and related results, while Tanaist retains ownership of its underlying platform.
Exclusive collaboration expands Parkinson’s platform
Lunai Bioworks entered an exclusive worldwide license and collaboration with Tanaist to expand its Parkinson’s disease discovery and validation platform.
The deal adds human cellular phenotyping to test whether AI-identified patient subtypes reproduce across cohorts and map to measurable cellular mechanisms. Lunai secured exclusive rights to Tanaist’s cellular phenotyping technology in Parkinson’s for programs based on Lunai patient phenoclusters.
